For dog owners

Rapamycin and dogs: what is claimed, and what is shown

Dogs are where nearly all of the companion-animal evidence lives — a randomized trial in pet dogs, and the largest longevity trial ever run in a companion animal still under way. That is more than any other species has, and it is still less than the marketing suggests.

What applies to my dog?I have a cat instead

An old labrador with a greying muzzle sitting calmly indoors, looking towards the camera

No drug has been shown to extend the lifespan of a dog.

Dogs have the best evidence in this field. They still do not have proof. Everything below separates what sellers claim from what the literature actually supports — and rapamycin is a prescription drug in every case, so none of this is a decision to make without a veterinarian.

Before anything is wrong

Starting early: the healthspan case

The strongest version of the longevity argument is preventive — beginning in middle age, while the animal is still well. Every trial in this field dosed animals at that stage.

Healthy ageing / healthspan

Emerging evidence

What is claimed

That low-dose rapamycin started in middle age slows the pace of ageing itself — keeping a dog active, mobile, and disease-free for longer, rather than treating any one condition.

What the evidence shows

This is the best-supported use, and it is still unproven in dogs. Rapamycin extended lifespan in mice from three independent labs, including when started in middle age. In dogs, a randomized trial in 24 middle-aged pets found ten weeks of low-dose rapamycin well tolerated. The trial built to answer the lifespan question — TRIAD — is still running and has not reported. Nobody can yet tell you it works.

Rapamycin: the most-studied longevity drug in biology, and what it means for dogs and cats→Why big dogs die young→Study: Nature 2009→Study: GeroScience 2017→Study: Dog Aging Project 2024→

Condition by condition

If your dog already has a diagnosis

These are the specific uses rapamycin is marketed for in dogs. Each claim is stated as its proponents make it, then set against the evidence — including where no trial exists at all.

Heart function

Early evidence

What is claimed

That rapamycin prevents age-related stiffening of the heart muscle and thickening of the left ventricular wall, keeping pumping capacity closer to a younger dog's.

What the evidence shows

This is the strongest signal in the canine data — and it comes from one small study. In the 2017 randomized trial, echocardiography showed improvement in age-associated measures of heart function after ten weeks. Twenty-four dogs, ten weeks, not designed to prove a clinical benefit. It is a reason to keep studying, not a treatment.

The ageing dog's heart — and the one place a rapamycin trial actually saw something→Rapamycin: the most-studied longevity drug in biology, and what it means for dogs and cats→Study: GeroScience 2017→Study: Dog Aging Project 2024→

Joints and mobility (osteoarthritis)

Early evidenceNo trial in this species

What is claimed

That by damping systemic inflammation and cartilage breakdown, rapamycin improves mobility and reduces stiffness and pain in older dogs.

What the evidence shows

There is no controlled trial of rapamycin for canine osteoarthritis. The mechanism is plausible on paper — mTOR is involved in cartilage biology and inflammatory signalling — but plausible mechanisms fail in trials all the time. Meanwhile, weight control, pain management, and physiotherapy have real evidence for canine arthritis and should come first.

Dog arthritis: what actually helps, and where rapamycin fits (it doesn't, yet)→Five things with better evidence than any longevity drug→

Cancer risk

Animal-model evidenceNo trial in this species

What is claimed

That by triggering autophagy — the cell's clearing of damaged components — rapamycin prevents damaged and cancerous cells from accumulating, lowering tumour incidence in older dogs.

What the evidence shows

No trial has shown rapamycin reduces cancer incidence in dogs. The autophagy mechanism is genuine and mTOR inhibitors are used in human oncology as treatments, not preventives. TRIAD records cancer among its outcomes, so this may eventually have an answer — it does not have one now. Given how many dogs die of cancer, the temptation to overstate here is strong, and worth resisting.

Cancer in dogs: the real risk, the prevention claims, and what evidence supports→Study: Dog Aging Project 2024→Study: Nature 2009→

Cognitive decline (canine dementia / CDS)

Early evidenceNo trial in this species

What is claimed

That by reducing neuroinflammation, rapamycin slows Canine Cognitive Dysfunction Syndrome — the disorientation, disrupted sleep, and failure to recognise family seen in old dogs.

What the evidence shows

There is no controlled trial of rapamycin for canine cognitive dysfunction. TRIAD includes cognitive measures, so an answer may come. It is worth noting what happened next door: spermidine, another autophagy inducer with an excellent mechanism, failed to show cognitive benefit in its largest human trial. Mechanism is not proof. Have the vet rule out treatable causes — pain, sensory loss, systemic illness — before assuming dementia.

Old dog, confused at night: canine cognitive dysfunction explained→Spermidine and fisetin: promising, and still early — on purpose→Study: Dog Aging Project 2024→

The primary literature

Studies run in dogs

5 studies in this species, with sample sizes and honest evidence grades.

Full study library →

Aging cohortsEarly evidenceOngoing — no result yet

LOY-002 — FDA reasonable expectation of effectiveness for extending senior dog lifespan

Loyal (Cellular Longevity, Inc.) · FDA Center for Veterinary Medicine, 2025

The FDA's veterinary center accepted that there is a reasonable expectation of effectiveness for a daily drug intended to extend the lifespan of senior dogs — a milestone on the conditional-approval path, not a full approval.

Species: Dogs
Design: Regulatory milestone
Sample: STAY study — approximately 1,000 senior dogs

Rapamycin & mTOREmerging evidenceOngoing — no result yet

TRIAD — Test of Rapamycin In Aging Dogs

Dog Aging Project (Kaeberlein M., Promislow D.E.L. et al.) · Dog Aging Project, 2024

A double-blind, placebo-controlled trial testing whether low-dose rapamycin extends lifespan and healthspan in older companion dogs. Results are not yet published — we will not characterize an outcome that does not exist.

Species: Dogs
Design: Randomized controlled trial
Sample: Several hundred older, large-breed companion dogs

Aging cohortsEmerging evidence

An open science study of ageing in companion dogs

Creevy K.E., Akey J.M., Kaeberlein M., Promislow D.E.L. et al. · Nature, 2022

Establishes a large, open, longitudinal cohort of pet dogs — with owner surveys, veterinary records, and biospecimens — designed to identify the genetic, environmental, and lifestyle determinants of healthy canine aging.

Species: Dogs
Design: Cohort study
Sample: Tens of thousands of companion dogs across the United States

Rapamycin & mTOREmerging evidence

A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs

Urfer S.R., Kaeberlein T.L., Mailheau S. et al. · GeroScience, 2017

Ten weeks of low-dose rapamycin in healthy middle-aged dogs was well tolerated, with no significant increase in adverse events over placebo. Echocardiography showed improvements in age-associated measures of heart function.

Species: Dogs
Design: Randomized controlled trial
Sample: 24 middle-aged companion dogs

Aging cohortsEmerging evidence

The dog aging project: translational geroscience in companion animals

Kaeberlein M., Creevy K.E., Promislow D.E.L. · Mammalian Genome, 2016

Lays out the case for the companion dog as a translational model of aging, and for testing geroprotective interventions — rapamycin foremost among them — in animals that actually live alongside us.

Species: Dogs
Design: Review

Not sure what applies to your dog?

Message us on WhatsApp and one of our veterinarians will help you work out whether any of this is relevant to your animal — and say so plainly when it isn't.

Ask on WhatsApp

A conversation, not a prescription. Anything for your pet still goes through a veterinarian who has examined them.

The content on this site is for informational purposes only and is not veterinary advice. These statements have not been evaluated by a food or drug regulatory authority and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a licensed veterinarian about your pet's health.